Tandem Diabetes Care, Inc. (Nasdaq: TNDM) has appointed Jeannette Bankes as president and chief executive officer, effective 16 November 2026, as the insulin delivery technology company enters a new phase focused on international expansion, reimbursement reform and sustainable profitability. Announced on 5 November alongside third-quarter results showing 14% revenue growth to US$283.7 million, the planned transition will see Bankes succeed John Sheridan, who will retire at the end of 2026 after more than a decade with the company.
The appointment brings an experienced global medical technology executive into a business that has expanded its automated insulin delivery portfolio while working to improve the economics of its commercial operations. Bankes most recently led GE HealthCare’s US$3.1 billion Patient Care Solutions segment, giving her experience in managing large medical technology businesses across clinical, commercial and operational functions.
Tandem Diabetes Care‘s immediate challenge is no longer limited to increasing insulin pump shipments. The company is expanding pharmacy-based reimbursement, introducing products into additional international markets and attempting to improve margins while continuing to invest in automated insulin delivery technology. Bankes will inherit a business showing measurable financial improvement, but one that has not yet achieved sustained GAAP profitability.
Why has Tandem Diabetes Care selected Jeannette Bankes to lead its next growth phase?
The appointment follows a board-led succession and search process intended to preserve continuity while positioning Tandem Diabetes Care for its next stage of development. Bankes will join the company’s board of directors when she assumes the chief executive role on 16 November.
She brings more than 30 years of healthcare industry experience, including leadership positions covering product development, commercial strategy, regulatory affairs, clinical operations and manufacturing. Her career includes senior responsibilities at GE HealthCare, Alcon, Boston Scientific and Merck.
Most recently, Bankes served as president and chief executive officer of GE HealthCare’s Patient Care Solutions segment, a business generating approximately US$3.1 billion in annual revenue. The division includes patient monitoring, diagnostic cardiology, maternal and infant care, and anaesthesia solutions.
That experience is relevant because Tandem Diabetes Care operates in a medical technology market where commercial success depends on more than the performance of the device itself. Manufacturers must coordinate hardware development, software innovation, regulatory compliance, clinical education, distribution and reimbursement across different healthcare systems.
Before joining GE HealthCare, Bankes served as senior vice-president and president of global franchises at Alcon. Her responsibilities included product development, portfolio management and commercialisation across surgical, vision care and ocular health businesses.
This background provides experience in managing portfolios that combine clinical technology with substantial operational and commercial requirements. However, insulin delivery systems also involve specialised challenges related to ongoing patient use, digital connectivity, consumable supplies and reimbursement structures.
Board chair Beckie Robertson indicated that Bankes’ operational experience and ability to translate innovation into commercial performance were central to the appointment. The board’s stated priority is to maintain product development momentum while building a more consistently profitable business.
Bankes, meanwhile, has identified product innovation, expanded access and disciplined execution as priorities for her tenure. The effectiveness of that strategy will depend on how successfully Tandem Diabetes Care converts technology investment and increasing adoption into sustained financial returns.
What does John Sheridan’s retirement mean for Tandem Diabetes Care’s existing strategy?
John Sheridan has led Tandem Diabetes Care as president and chief executive officer since 2019, having joined the company as chief operating officer in 2013. His tenure includes the expansion of the company’s automated insulin delivery systems and the development of its international commercial operations.
Sheridan will remain an employee through the end of 2026 and subsequently serve as a consultant to support the transition. This arrangement suggests that the company is seeking continuity rather than an abrupt change in strategic direction.
The leadership transition occurs after Tandem Diabetes Care established a broader technology portfolio built around its t:slim X2 insulin pump and Tandem Mobi system. Both are part of the company’s automated insulin delivery offering and incorporate Control-IQ+ advanced hybrid closed-loop technology.
Sheridan also oversaw efforts to expand reimbursement access and introduce alternative purchasing models. These initiatives are particularly important because insulin pump adoption can be influenced by the way devices and consumables are funded through healthcare systems.
In the November announcement, Sheridan highlighted the company’s technology development and its reported reach among approximately half a million people worldwide who benefit from Tandem technology. That figure reflects the company’s description of its global user population rather than a new clinical outcome finding.
For Bankes, the transition creates an opportunity to build on an established product portfolio rather than begin with a major restructuring. However, maintaining continuity does not eliminate the need to address financial performance, competition and changing customer expectations.
The success of the leadership change will be measured partly by whether improvements in revenue, reimbursement access and operating efficiency continue after the transition.
How do Tandem Diabetes Care’s third-quarter results change the financial outlook for its incoming CEO?
Tandem Diabetes Care reported worldwide third-quarter sales of US$283.7 million, increasing 14% from US$249.3 million in the corresponding period of 2025.
United States sales reached US$191.0 million, an increase of 9%, while international revenue rose 26% to US$92.6 million. International growth reached 27% on a constant-currency basis, indicating that foreign exchange movements modestly affected reported performance.
The company shipped approximately 33,000 insulin pumps worldwide during the quarter, including nearly 23,000 in the United States and nearly 11,000 internationally. Both geographic markets recorded higher shipment volumes than a year earlier.
Gross profit increased to US$160.4 million from US$134.3 million, while the gross margin improved to approximately 57%. The company reported an increase of 270 basis points in gross margin compared with the third quarter of 2025.
Operating performance improved substantially. Tandem Diabetes Care reduced its quarterly operating loss to US$2.4 million from US$22.9 million, with the operating margin improving by approximately 830 basis points.
Its net loss narrowed to US$7.1 million from US$21.2 million. Adjusted EBITDA increased to US$18.0 million from US$2.8 million, equivalent to approximately 6% of quarterly sales.
These results show meaningful progress towards operating profitability, although the company remains loss-making under generally accepted accounting principles. Adjusted EBITDA excludes certain expenses and should not be treated as equivalent to net income or free cash flow.
The improvements also provide a stronger starting point for Bankes than a business experiencing simultaneous revenue contraction and rising operating losses. Nevertheless, sustaining margin expansion will require continued control over manufacturing, distribution and operating expenses.
The company reaffirmed full-year 2026 sales guidance of US$1.065 billion to US$1.085 billion. It also maintained expectations for a gross margin of approximately 56% to 57% and an adjusted EBITDA margin of 5% to 6%.
These projections establish a near-term financial benchmark against which investors can evaluate the transition. The incoming chief executive will ultimately be assessed on whether the company can extend those improvements into 2027 and beyond.
Why is Tandem Diabetes Care’s pay-as-you-go reimbursement model central to its strategy?
One of the most important changes underway at Tandem Diabetes Care concerns how patients obtain insulin pump technology. The company has been expanding a pay-as-you-go reimbursement model that shifts more business through the pharmacy channel.
During the third quarter, approximately 15% of United States sales came through the pharmacy channel. Tandem Diabetes Care also reported that pharmacy formulary coverage had expanded to approximately 50% of covered lives in the United States.
These figures indicate progress in establishing an alternative access model, but they describe different measures. The 15% figure concerns actual sales through the pharmacy channel, while the 50% figure refers to formulary coverage rather than the proportion of patients actively using Tandem products.
A pharmacy-based model can change the financial and operational relationship between manufacturers, insurers, healthcare providers and patients. Traditional durable medical equipment arrangements often involve distinct purchasing, reimbursement and replacement processes.
An alternative model may simplify access for some patients and reduce administrative barriers, depending on the terms of their insurance coverage. However, formulary inclusion does not guarantee that every covered patient qualifies for a device or can obtain it without restrictions.
The changing reimbursement model also complicates interpretation of quarterly sales. In the United States, Tandem Diabetes Care’s pump revenue declined 2% to US$83.4 million even though pump shipments increased.
At the same time, United States supplies and other revenue rose 19% to US$107.7 million. This divergence is consistent with a business model transition in which device shipment volumes and the timing or composition of recognised revenue do not necessarily move together.
The distinction is particularly important for investors evaluating sales growth. Higher pump shipments do not automatically translate into proportional increases in upfront pump revenue, especially as reimbursement and product mix change.
For Bankes, successful execution will depend on whether the new model expands access while maintaining attractive economics over the customer relationship.
How will Tandem Mobi and Control-IQ+ influence the company’s competitive position?
Tandem Diabetes Care’s commercial strategy centres on automated insulin delivery systems that combine insulin pumps with glucose monitoring information and software designed to assist insulin dosing.
Its current portfolio includes the Tandem Mobi system and the t:slim X2 insulin pump, both incorporating Control-IQ+ advanced hybrid closed-loop technology. The systems are designed to reduce aspects of the daily management burden associated with insulin therapy, although users must continue performing responsibilities specified in the applicable instructions and clinical guidance.
Automated insulin delivery is an increasingly competitive medical device category. Patients and healthcare professionals evaluate products according to glucose-management performance, device size, usability, sensor compatibility, training requirements and reimbursement access.
Tandem Diabetes Care has expanded compatibility between its t:slim X2 system and Abbott’s FreeStyle Libre 3 Plus Sensor to 11 international markets. The company has also announced Tandem Mobi availability in 12 countries outside the United States.
These developments broaden the potential customer base and provide more device and sensor options in participating markets. However, product availability and compatibility must be understood according to the specific authorised configurations and jurisdictions.
An integration authorised in one country or for one device configuration should not be assumed to apply automatically to every Tandem product or all international markets. Software and medical device compatibility require appropriate validation and regulatory compliance.
For clinicians, interoperability can influence treatment selection because patients may already use a particular continuous glucose monitoring system. Expanding compatible options can support flexibility, but the clinical and operational suitability of a configuration still depends on patient needs and its authorised use.
Bankes will need to balance continued innovation with the practical requirements of commercial scale. New technology may attract users, but manufacturers must also provide training, technical support, product availability and dependable software maintenance.
The competitiveness of Tandem’s portfolio will therefore be determined by both product performance and the experience of using and supporting the technology over time.
Why could international expansion become increasingly important under Jeannette Bankes?
International sales reached US$92.6 million during the third quarter, increasing 26% from US$73.6 million a year earlier. This growth outpaced the 9% increase recorded in the United States, making international operations an important contributor to the company’s overall expansion.
The company shipped nearly 11,000 pumps internationally during the quarter, compared with more than 9,000 a year earlier. The expansion of Tandem Mobi availability and sensor compatibility has also broadened its presence across additional markets.
However, international commercial development introduces operational complexity. Reimbursement structures, device procurement processes, clinical practice patterns and regulatory requirements can vary significantly between countries.
Tandem Diabetes Care has been pursuing direct commercial operations in selected international markets, a transition that can provide greater control over customer relationships but may also increase infrastructure and operating requirements.
A direct model typically requires investment in sales teams, customer support, distribution and regional management. The financial benefits depend on whether higher sales and improved commercial control outweigh those additional costs.
Bankes’ experience managing international healthcare technology businesses may be particularly relevant to this phase. Nevertheless, the specific economics of Tandem’s international operations will depend on country-level performance, reimbursement arrangements and product adoption.
The challenge is to maintain strong geographic growth without allowing the costs of commercial expansion to erode the margin improvements already achieved.
What does the $10 million inducement equity award reveal about Tandem Diabetes Care’s leadership investment?
Tandem Diabetes Care’s board approved an inducement award for Bankes consisting of restricted stock units with an aggregate value as close as practicable to, but not exceeding, US$10 million.
The number of shares will be determined using the company’s average closing share price over a specified 15-trading-day period preceding the grant date. The award is scheduled to become effective on 15 December 2026.
One-third of the restricted stock units will vest on the first anniversary of the grant date, with the remaining two-thirds vesting in eight equal quarterly instalments thereafter. The structure therefore extends the vesting schedule across multiple years rather than delivering the entire award immediately.
The award was approved outside the company’s existing long-term incentive plan under the applicable Nasdaq inducement grant provision. Tandem Diabetes Care stated that it was intended partly to compensate Bankes for unvested equity awards forfeited when leaving her previous employer.
These terms are important because the US$10 million headline value should not be described as an immediate cash payment or as compensation already received. The ultimate economic value of the restricted shares will depend on vesting and the company’s stock price.
For shareholders, equity compensation can create dilution, although the size of the effect depends on the final number of shares granted and changes in the outstanding share count.
The award also illustrates the scale of the company’s investment in securing an experienced external executive. It provides an incentive linked to continued service, while the broader assessment of executive compensation will depend on the company’s complete remuneration arrangements and subsequent performance.
Tandem Diabetes Care said additional information would be included in its 2027 annual meeting proxy statement. That disclosure will provide further context for evaluating the appointment’s compensation structure.
How are Tandem Diabetes Care investors responding to the leadership transition and financial results?
Tandem Diabetes Care shares closed at US$17.99 on 5 November 2026, declining 5.56% during the regular trading session. The stock had closed at US$19.05 on 4 November and US$19.11 on 30 October.
The shares remained approximately 11.3% above their 6 October closing level of US$16.16, illustrating a positive one-month movement despite the subsequent decline.
The reported 52-week trading range was US$12.26 to US$29.65, with a market capitalisation of approximately US$1.25 billion at the 5 November closing price.
The leadership announcement and third-quarter results were released after the regular trading session. The same-day decline therefore cannot be attributed to market reaction to the newly announced succession or the quarterly financial disclosures.
Investor sentiment is likely to reflect several simultaneous considerations. Revenue growth and margin expansion provide evidence of improving operations, while the continued GAAP net loss demonstrates that the profitability transition remains incomplete.
The company’s financial position also provides context. Tandem Diabetes Care held approximately US$443.1 million in cash, cash equivalents and short-term investments at 30 September 2026, compared with US$292.7 million at the end of 2025.
However, the balance sheet included approximately US$603.4 million in long-term convertible senior notes. Gross liquidity therefore should not be considered independently of the company’s financial obligations and future investment requirements.
The positive operating trends may support confidence in management’s strategy, but the competitive insulin delivery market requires continued research, product development and commercial investment.
For the incoming chief executive, the principal market test will be whether Tandem Diabetes Care sustains double-digit growth while improving its underlying profitability and maintaining a competitive product portfolio.
What must Jeannette Bankes deliver during her first year as Tandem Diabetes Care CEO?
The most immediate responsibility will be ensuring a stable leadership transition while maintaining the company’s existing financial and commercial momentum. Bankes assumes the chief executive role on 16 November, with Sheridan remaining available through the transition period.
A central operating priority will be the continued expansion of pharmacy-based reimbursement. The company has already reported meaningful progress in formulary coverage and sales through the pharmacy channel, but further adoption will need to produce sustainable revenue and margin outcomes.
International growth will provide another important performance indicator. Tandem Diabetes Care has expanded product availability across additional countries, but the economics of direct operations and the ability to support a larger installed customer base remain important.
Product development will also require continued attention. Tandem Mobi, t:slim X2 and Control-IQ+ provide an established portfolio, while the company must continue adapting to changing sensor technologies, patient preferences and competitive products.
The company’s third-quarter margin improvements offer an encouraging starting point, but adjusted EBITDA profitability does not remove the requirement to establish consistent GAAP profitability. A durable improvement would require operating gains that persist beyond individual quarters and remain supported by cash generation.
Bankes’ medical technology background provides experience relevant to these challenges, particularly in commercial execution, global operations and portfolio management. However, the appointment itself does not establish that Tandem Diabetes Care will outperform competitors or achieve its long-term financial objectives.
The November succession marks a transition from a period heavily associated with product development and platform expansion towards one in which the financial benefits of those investments are increasingly measurable.
For Tandem Diabetes Care, the critical milestones under Bankes will be continued insulin pump adoption, successful implementation of new reimbursement models, international sales growth and conversion of improving operating margins into sustainable profitability. The company’s next phase will depend on whether those commercial achievements can be delivered while preserving the innovation and clinical support required in automated insulin delivery.
